KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 92 days ( 0 % )
Last Price $0.311 0 %
High/ Low $0.311 - $0.311 0%
Chg 7 Days N/A $0.311 $0.311
Chg 30 Days N/A $0.311 $0.311
Chg 12 mos -13.93 % $0.361 $0.311
Trend - 3 mos N/A Width: 0 %
Trend - 12 mos -2.87 % Width: 65.83 %
Pred. range - 3 mos N/A - N/A -100.00 % - -100.00 %
Pred. range - 12 mos $0.213 - $0.354 -31.32 % - 13.89 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Buy Sep 12, 2022 - 96 days
Long MA avg 12 mos Buy Sep 14, 2022 - 94 days
Short/Long MA avg 12 mos Buy Sep 22, 2022 - 88 days
Pivot Short Sell Jan 26, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Tyme Technologies Inc

Tyme Technologies Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the ... TYME Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT